

July 9, 2003

Patricia Power B.Sc., Ph.D. (Chem.)  
416 957 1683 ppower@bereskinparr.com

Your Reference: 09/600,125  
Our Reference: 10242-32

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

The Commissioner of Patents  
& Trademarks  
Washington, D.C. 20231  
U.S.A.

RECEIVED  
JUL 16 2003  
TECH CENTER 1600/2900  
PM 3:40  
03 JUL 16 2003

07/15/2003 RHARMON 00000015 09600125

01 FC:1806 Dear Sir: 180.00 OP

**Re: U.S. Patent Application No. 09/600,125**

**Filed: April 10, 2002**

**Title: COMPOSITION CONTAINING PROPARGLYAMINE  
FOR ENHANCING CANCER THERAPY**

**Inventors: R.C. Warrington, I. Alick Paterson and Alan A. Boulton**

In accordance with 37 CFR 1.97 and 1.98, and in recognition of the duty of disclosure set forth in 37 CFR 1.56, Applicants hereby submit a Supplemental Information Disclosure Statement on Form PTO-1449 containing a listing of patents and other publications of which Applicant is aware. Applicants are also submitting the references listed on the Supplemental Information Disclosure Statement.

All of the patents and publications submitted herewith are in the English language. Accordingly a concise explanation of the relevance of the documents is not required.

The Examiner is requested to indicate consideration of these documents by initialing the appropriate column.

Applicants reserve the right to contest the applicability of any of these documents as prior art against the subject application. If the Examiner has any questions concerning this Supplemental Information Disclosure Statement, he/she is requested

please send your reply to

Meadowvale Corporate Centre, 2000 Argentia Road  
Plaza 4, Suite 430, Mississauga, Ontario, Canada L5N 1W1  
t: 905 812 3600 f: 905 814 0031

Scotia Plaza, 40 King Street West, 40th Floor  
Toronto, Ontario, Canada M5H 3Y2  
t: 416 364 7311 f: 416 361 1398


to contact the undersigned. Entry of the enclosed Supplemental Information Disclosure Statement is believed to be in order and is respectfully requested.

The fee of \$180.00 for the filing of the enclosed Supplemental Information Disclosure Statement is included in our cheque #5446 enclosed herewith.

If any further charge is required please charge our Deposit Account No. 02-2095.

Respectfully submitted,

**R.C. WARRINGTON et al.**

A handwritten signature in cursive script, appearing to read 'P. Power', is written over a horizontal line.

Patricia Power

Registration No. 51,379

Dated: July 9, 2003

Bereskin & Parr  
Box 401, 40 King Street West  
Toronto, Ontario, Canada  
M5H 3Y2

(416) 364-7311

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

*(use as many sheets as necessary)*

Sheet	1	of	2
-------	---	----	---

**C mplete if Known**

Application Number	09/600,125
Filing Date	April 10, 2002
First Named Inventor	R.C. Warrington
Group Art Unit	1614
Examiner Name	Frederick Krass
Attorney Docket Number	10242-32

## U.S. PATENT DOCUMENTS

[illegible]

## FOREIGN PATENT DOCUMENTS

[illegible]

**Examiner  
Signature**

Date  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04.

<sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Assistant Commissioner for Patents, Washington, DC 20231.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 2 of 2

**Complete if Known**

Application Number	09/600,125
Filing Date	April 10, 2002
First Named Inventor	R.C. Warrington
Group Art Unit	1614
Examiner Name	Frederick Krass
Attorney Docket Number	10242-32

**OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	1.	WARRINGTON, R.C. et al., "Modulation of anticancer drug toxicity by L-histidinol: A route for improving human cancer chemotherapy?", Drugs of the Future, 1993, pp. 743-749	
	2.	WARRINGTON, R.C. et al., "L-Histidinol in experimental chemotherapy: improving the selectivity and efficacy of anticancer drugs, eliminating metastatic disease and revering the multi-drug resistant phenotype", Biochemistry & Cell Biology, 1992, pp. 365-375, Vol. 70.	
	3.	WARRINGTON, R.C. et al., "Hitidinol-Mediated Enhancement of the Specificity of Two Anticancer Drugs in Mice Bearing Leukemic Bone Marrow Disease", Journal of the National Cancer Institute, 1985, pp. 1070-77, Vol. 71.	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.